Barry, what you gonna do now?

Quote


















anonymous said:
Barry has no desire to win. Embarrassing.
Click to expand...

We need Joe Biden’s doctor to pay Barry a visit and give him a testosterone shot before the next investor conference. Obviously we don’t ever have any good news to share but if we can at least get him pumped to share how bright the future looks (we know he’s good at lying about this) instead of putting everybody to sleep, then maybe Wall Street will show us some love before the holidays.
 






anonymous said:
We need Joe Biden’s doctor to pay Barry a visit and give him a testosterone shot before the next investor conference. Obviously we don’t ever have any good news to share but if we can at least get him pumped to share how bright the future looks (we know he’s good at lying about this) instead of putting everybody to sleep, then maybe Wall Street will show us some love before the holidays.
Click to expand...

Worst CEO, management team and biopharm company I’ve seen. Way to go Barry, what was stock price 9 years ago? Same as today’s close.

Bozos.
 






anonymous said:
We need Joe Biden’s doctor to pay Barry a visit and give him a testosterone shot before the next investor conference. Obviously we don’t ever have any good news to share but if we can at least get him pumped to share how bright the future looks (we know he’s good at lying about this) instead of putting everybody to sleep, then maybe Wall Street will show us some love before the holidays.
Click to expand...

One of the main things that bothers me about Barry (although there are a few others), is how he always paints a picture to the investment community that just flat out doesn't align with the reality of what we know internally within the company. I'm not saying that most inside the company don't believe we can eventually succeed, particularly with making Zynrelef a respectably selling product for post-op pain; but when Barry goes off and speaks to the investment community at these conferences he makes it sound like EVERYTHING is going perfectly with no challenges or misgivings whatsoever. He's been doing it for years, and we all know what a bump ride it's been for us along the way. I think it's one thing to exhibit optimism about the mission you are pursuing with your company, but its a whole nother thing to be painting a false narrative of what's actually occurring with your business at a given time. I really wish he'd just narrow the wide gap between the "everything-is-peachy" BS he spews at investor conferences and the reality that's very clear within. But I won't hold my breath...
 






anonymous said:
One of the main things that bothers me about Barry (although there are a few others), is how he always paints a picture to the investment community that just flat out doesn't align with the reality of what we know internally within the company. I'm not saying that most inside the company don't believe we can eventually succeed, particularly with making Zynrelef a respectably selling product for post-op pain; but when Barry goes off and speaks to the investment community at these conferences he makes it sound like EVERYTHING is going perfectly with no challenges or misgivings whatsoever. He's been doing it for years, and we all know what a bump ride it's been for us along the way. I think it's one thing to exhibit optimism about the mission you are pursuing with your company, but its a whole nother thing to be painting a false narrative of what's actually occurring with your business at a given time. I really wish he'd just narrow the wide gap between the "everything-is-peachy" BS he spews at investor conferences and the reality that's very clear within. But I won't hold my breath...
Click to expand...

Barry has no credibility with investors for exactly the reasons you describe, he says everything looks great and Heron NEVER delivers. That’s why you receive no stock price premium for the future promises - your track record sucks.

Zynrelef is a potentially good product in hands of crappy management team. Just sell the company.
 






anonymous said:
Barry has no credibility with investors for exactly the reasons you describe, he says everything looks great and Heron NEVER delivers. That’s why you receive no stock price premium for the future promises - your track record sucks.

Zynrelef is a potentially good product in hands of crappy management team. Just sell the company.
Click to expand...

Its time for Barry to admit he’s in over his head here. No doubt Z sales will be very slow and we’ll get a few more CRLs before he’s gone.
 






anonymous said:
Barry has no credibility with investors for exactly the reasons you describe, he says everything looks great and Heron NEVER delivers. That’s why you receive no stock price premium for the future promises - your track record sucks.

Zynrelef is a potentially good product in hands of crappy management team. Just sell the company.
Click to expand...

Logical to say just sell the company now but it's a lot more complex than that since we already have fully invested in the initial launch of Zynrelef. Whoever would be considering buying us would be better off waiting until Zynrelef has been out there in the market for at least a year and the surgical procedure environment fully recovered to pre-COVID levels. I think a suitor buying and integrating us at this point in time would probably cause a good amount of disruption (current sales force would largely be blown out -- yay! so fun), subsequently hindering the launch trajectory of Zynrelef which in turn may even have unfavorable ramifications for market adoption further down the line. All that said, the suitor would probably be getting a good bargain price on us today so maybe those risks are worth taking. I really don't know.

And then there is the question of whether Barry and the Board would even accept a buyout offer at this point. My guess is they wouldn't because they are completely oblivious to reality.

In the end, nothing will happen, nothing will change, and we'll be back on this message board a year from now airing our grievances once again. Can't wait.
 






Why would any company buy later if Z is such a great product? Buy now while stock is low, almost in the $9 range on Friday.
Oh that’s right, Z is just a second in class, difficult to administer, non-opioid with questionable efficacy and a black box. Not designed for anesthesiologists, the pain control specialists. With a BS’er at the helm who has a reputation of misrepresentation things to investors it can’t get much worse.
Plus you hired a bunch of Pacira failures who were looking for a get rich quick opportunity. Sounds like a fun place to be, enjoy.
 






anonymous said:
Why would any company buy later if Z is such a great product? Buy now while stock is low, almost in the $9 range on Friday.
Oh that’s right, Z is just a second in class, difficult to administer, non-opioid with questionable efficacy and a black box. Not designed for anesthesiologists, the pain control specialists. With a BS’er at the helm who has a reputation of misrepresentation things to investors it can’t get much worse.
Plus you hired a bunch of Pacira failures who were looking for a get rich quick opportunity. Sounds like a fun place to be, enjoy.
Click to expand...

Couldn't have said it better myself!!!
 






anonymous said:
Why would any company buy later if Z is such a great product? Buy now while stock is low, almost in the $9 range on Friday.
Oh that’s right, Z is just a second in class, difficult to administer, non-opioid with questionable efficacy and a black box. Not designed for anesthesiologists, the pain control specialists. With a BS’er at the helm who has a reputation of misrepresentation things to investors it can’t get much worse.
Plus you hired a bunch of Pacira failures who were looking for a get rich quick opportunity. Sounds like a fun place to be, enjoy.
Click to expand...

Barry became CEO in 2013. On Nov 22 2013 stock closed at $9.50 which is about where we are 8 years later.

The number one job of the CEO is to create value for shareholders.

Barry Quart is an abject failure and should be replaced. In fact the whole leadership team and head of CMC should be replaced.

Pure incompetence.
 






anonymous said:
Why would any company buy later if Z is such a great product? Buy now while stock is low, almost in the $9 range on Friday.
Oh that’s right, Z is just a second in class, difficult to administer, non-opioid with questionable efficacy and a black box. Not designed for anesthesiologists, the pain control specialists. With a BS’er at the helm who has a reputation of misrepresentation things to investors it can’t get much worse.
Plus you hired a bunch of Pacira failures who were looking for a get rich quick opportunity. Sounds like a fun place to be, enjoy.
Click to expand...

Eye take ofence too bean kawled a Pracira Phailyour.
 






anonymous said:
Eye take ofence too bean kawled a Pracira Phailyour.
Click to expand...

I think Heron Mgmt is simply outclassed by Pacira. Look at their BOD vs ours, they have an ex Governor and we have a bunch of Kevin Tang (failure) chronies. Barry might know development but Stack knows business and how to play the game and Pacira is destroying us on all fronts. Maybe someone needs to send Barry across the street to Pacira with a disguise and a notepad to figure out how it’s done. This company is heading BK with Barry at the helm.
 




































anonymous said:
Barry is enough of a moron to do a raise at all time lows in stock price. At least we know our options are worthless.
Click to expand...

He's going to have to raise more money at some point in the next few months. Last I did the math, we are going to run out of money within the next 12-15 months. I know they are saying that we'll burn less and less each month or quarter going forward, and that we'll have enough cash for well beyond 12-15 months, but I just don't find that realistic at all. When I look around, i see more money being spent, not less and it's not like we we are selling all that much more than we did earlier this year. The CINV business is stagnant at best. Zynrelef will ramp but not to some magical extent that outpaces the amount of commercial resources we are putting behind it at this point. And nobody ever seems to talk about this but our gross margins are terrible! That's what happens when your strategy is to basically try to undercut competition on price. It didn't work for CINV, and TBD if it works on Zynrelef. But it sure as heck doesn't seem to be a winning long-term strategy when you are only keeping like 50 cents on every dollar of a drug you sell. That's what generic drug companies do but the difference is that they don't have to pay an entire sales force to drive demand in the field. It's truly amazing how our CEO has been able to keep his job after so many years of missteps and eroding shareholder value.
 






Top Bottom
Back
Quote